Agena, Simceredx to develop companion dx, 5/18
May 2018—Agena Bioscience and Simcere Diagnostics signed a strategic partnership agreement to expand the use of Agena’s MassArray System for companion diagnostics and pharmacogenetic testing in China.
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Erythroferrone ELISA kit, 5/18
May 2018—Intrinsic LifeSciences released its Erythroferrone IE ELISA kit for research use only. It is designed for quantification of human erythroferrone in serum and does not contain mercaptoethanol or azide- or mercury-based preservatives.
Thermo Fisher acquires IntegenX, 5/18
May 2018—Thermo Fisher Scientific has acquired IntegenX, a forensic DNA testing firm. IntegenX products include the RapidHIT platforms, software analysis tools, and related consumables that are compatible with Thermo Fisher’s short tandem repeat chemistries for human identification.
Randox teams up with Bosch, 5/18
May 2018—Randox Laboratories unveiled Vivalytic, a molecular diagnostics platform, with Bosch Healthcare Solutions at the 28th European Congress of Clinical Microbiology and Infectious Diseases, April 21–24, in Madrid.
Polyclonal antibodies, 5/18
May 2018—Binding Site’s Immunologicals Group announced the addition of sheep anti-human, monkey adsorbed, IgG polyclonal antibodies designed for use with a variety of testing procedures, especially enzyme immunoassays, for research applications.
Qiagen, Natera to develop genetic testing assays, 5/18
May 2018—Qiagen and Natera will partner to develop cell-free DNA assays, including for prenatal screening, for use on the Qiagen GeneReader NGS System.
Technopath, Beckman Coulter partner, 5/18
May 2018—Technopath Clinical Diagnostics, an Ireland-based developer and manufacturer of total quality control solutions for clinical laboratories, and Beckman Coulter Diagnostics signed a long-term supply and distribution agreement.
Foundation Medicine CGP assay available in U.S., 5/18
May 2018—Foundation Medicine announced that FoundationOne CDx, an FDA-approved comprehensive genomic profiling assay for all solid tumors incorporating multiple companion diagnostics, is available in the United States. FoundationOne CDx is a test for patients with advanced cancer and is offered as a nationally covered benefit across all solid tumors for Medicare and Medicare Advantage beneficiaries who meet eligibility requirements.
Helmer Scientific next-gen cell washer, 5/18
May 2018—Helmer Scientific announced the release of its FDA 510(k)-cleared, next-generation automatic cell washing system, the UltraCW II, for hospital blood banks and clinical laboratories. The UltraCW II automates steps within typical tube testing blood bank workflows. It removes plasma and unwanted antibodies from blood cells for pretransfusion testing procedures—ABO and Rh grouping, antibody identification, and cross-matching.
FDA clears donor screening tests for B. microti infection, 5/18
May 2018—The FDA approved Oxford Immunotec’s Imugen Babesia microti arrayed fluorescent immunoassay for the detection of antibodies to Babesia microti in human plasma samples and the Imugen Babesia microti nucleic acid test for the detection of B. microti DNA in human whole blood samples.